Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon

 
In response to the escalating situation and war on Lebanon, the Ministry of Public Health (MoPH) has developed and is currently implementing with all stakeholders the:
“National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon "

Developed through a collaborative approach by the National Mental Health Programme (NMHP) with the support of the World Health Organization, UNICEF, and all MHPSS Stakeholders (please refer to the action plan for a full list), this comprehensive plan outlines a proactive approach to anticipating, mitigating, and responding to the psychosocial impacts by focusing on early intervention and support to minimize the adverse effects on individuals, healthcare personnel and communities. It underscores the commitment of the MoPH and the NMHP to safeguard mental health and respond timely and effectively to the psychosocial needs of all populations residing in Lebanon during times of crisis while promoting their resilience.

Key Features of the Plan:
  • Continuity of MHPSS Services: The plan highlights actions to ensure the continued availability and accessibility of MHPSS services across Lebanon.
  • Assurance of Psychotropic Medications: The plan emphasizes ensuring the continuous supply and access to psychotropic medications to all old and new beneficiaries.
  • Communication and Messaging: The plan prioritizes the development and dissemination of key messages and tips on topics related to mental health and well-being that would promote community resilience.
  • Training and Capacity Building: The plan places a strong emphasis on training healthcare professionals and frontline responders in MHPSS principles and practices to provide effective support to service users and providers.
The MoPH is implementing this action plan with all stakeholders, including governmental bodies, local authorities and municipalities, non-governmental organizations, healthcare providers, frontliners, and the international community - Please do reach out if your organization is interested to join in implementing this crucial plan and working together to ensure the mental health and psychosocial support of Lebanon’s residents during times of adversity.

Kindly find a selection of valuable links below:
    5
ATC Name B/G Ingredients Dosage Form Price
R03BA02 BUDESONIDE ARROW G Budesonide - 1mg/2ml 1mg/2ml Inhalation suspension for nebuliser 1,342,499 L.L
R03BA02 BUDESONIDE ARROW G Budesonide - 1mg/2ml 1mg/2ml Inhalation suspension for nebuliser 1,342,499 L.L
C03CA02 BURINEX B Bumetanide - 1mg 1mg Tablet 335,961 L.L
R03BA02 BUDECORT G Budesonide - 1mg 1mg Respule 1,226,928 L.L
N07CA01 BETASERC B Betahistine dihydrochloride - 16mg 16mg Tablet 1,623,708 L.L
N07CA01 BETAHISTINE ARROW G Betahistine dihydrochloride - 16mg 16mg Tablet, scored 362,837 L.L
C09CA06 BLOPRESS B Candesartan cilexetil - 16mg 16mg Tablet 1,131,515 L.L
N07BC01 BUVIDAL B Buprenorphine - 16mg 16mg Injectable solution prolonged release 8,524,771 L.L
L01DC01 BLEOCIN B Bleomycin (sulfate) - 15U 15U Injectable lyophilised powder for solution 2,109,833 L.L
L01DC01 BLEO-CELL G Bleomycin (sulfate) - 15mg 15mg Injectable powder for solution 3,817,857 L.L
M05BA06 BONVIVA B Ibandronic acid - 150mg 150mg Tablet, film coated 1,265,900 L.L
M05BA06 BONAFOR G Ibandronic acid (monosodium monohydrate) - 150mg 150mg Tablet, film coated 383,955 L.L
A03AA04 BEVACOL 135 G Mebeverine HCl - 135mg 135mg Tablet, film coated 532,162 L.L
N07BC01 BUVIDAL B Buprenorphine - 128mg 128mg Injectable solution prolonged release 34,835,645 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 125mg 125mg Tablet, film coated 51,483,159 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 125mg 125mg Tablet, film coated L.L
S01LA06 BEOVU BioTech Brolucizumab - 120mg/ml 120mg/ml Injectable solution 44,309,066 L.L
S01LA06 BEOVU BioTech Brolucizumab - 120mg/ml 120mg/ml Injectable solution L.L
N02BE01 BBDOL-OR G Paracetamol - 120mg/5ml 120mg/5ml Syrup 188,138 L.L
N03AX23 BRIVIACT B Brivaracetam - 10mg/ml 10mg/ml Solution 10,314,804 L.L
C07AA05 BEDRANOL G Propranolol HCl - 10mg 10mg Tablet, film coated 247,267 L.L
C07AB07 B-COR 10 G Bisoprolol fumarate - 10mg 10mg Tablet, film coated 595,322 L.L
C07AB07 BISCORDEX G Bisoprolol fumarate - 10mg 10mg Tablet 789,667 L.L
C07AB07 BISOCOR 10 G Bisoprolol fumarate - 10mg 10mg Tablet, film coated 460,746 L.L
C07AB07 BISOPROLOL NORMON G Bisoprolol hemifumarate - 10mg 10mg Tablet, film coated 372,244 L.L
C07AB07 BISOPROLOL QUIVER LAB G Bisoprolol fumarate - 10mg 10mg Tablet, film coated, scored 526,786 L.L
C07AB07 BISOPROLOL REF G Bisoprolol hemifumarate - 10mg 10mg Tablet, coated, scored 544,256 L.L
A03BB01 BUSCOPAN B Butylscopolamine bromide - 10mg 10mg Tablet, sugar coated 692,079 L.L
A03BB01 BUSCOPAN B Butylscopolamine bromide - 10mg 10mg Tablet, sugar coated 291,614 L.L
N06AX26 BRINTELLIX B Vortioxetine - 10mg 10mg Tablet, film coated 4,345,987 L.L
    5
Sitemap
© Copyrights reserved to Ministry of Public Health 2025